IIIS - 2022 Conferences Proceedings

2022 Summer Conferences Proceedings

	Exploring Accountability for Sustainability and SDG in the Biopharmaceutical Industry Jean-Pierre Segers, Dirk V. Franco, Elina Gaile-Sarkane Proceedings of the 26th World Multi-Conference on Systemics, Cybernetics and Informatics: WMSCI 2022, Vol. II, pp. 130-135 (2022); https://doi.org/10.54808/WMSCI2022.02.130	The 26th World Multi-Conference on Systemics, Cybernetics and Informatics: WMSCI 2022 Virtual Conference July 12 - 15, 2022 Proceedings of WMSCI 2022 ISSN: 2771-0947 (Print) ISBN (Volume II): 978-1-950492-65-7 (Print)
	Authors Information \| Citation \| Full Text \| Jean-Pierre Segers Faculty of Engineering Economics and Management, Riga Technical University, Riga, Latvia / Faculty of Business Economics, Hasselt University, Diepenbeek, Belgium Dirk V. Franco Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium Elina Gaile-Sarkane Faculty of Engineering Economics and Management, Riga Technical University, Riga, Latvia Cite this paper as: Segers, J., Franco, D. V., Gaile-Sarkane, E. (2022). Exploring Accountability for Sustainability and SDG in the Biopharmaceutical Industry. In N. Callaos, E. Gaile-Sarkane, S. Hashimoto, B. Sánchez (Eds.), Proceedings of the 26th World Multi-Conference on Systemics, Cybernetics and Informatics: WMSCI 2022, Vol. II, pp. 130-135. International Institute of Informatics and Cybernetics. https://doi.org/10.54808/WMSCI2022.02.130 DOI: 10.54808/WMSCI2022.02.130 ISBN - Volume II: 978-1-950492-65-7 (Print) ISSN: 2771-0947 (Print) Copyright: © International Institute of Informatics and Systemics 2022 Publisher: International Institute of Informatics and Cybernetics
Abstract Concerns about the global climate change, have put sustainability, the sustainable development goals and ESG (Environment, Social and Governance) at the top of the agenda of governments and industries and the multiple stakeholder groups they interact with. This paper explores the accountability for sustainability and of ESG-ratings in a selected industry – i.e., biopharmaceuticals – supported by evidence from exemplary case companies in the biopharma ecosystem in Belgium.
Full Text